Nexalin Technology, Inc.

Equities

NXL

US65345B2016

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 21:30:01 04/06/2024 BST			5-day change	1st Jan Change
0.71 ^USD	-1.39%		-22.40%	+75.40%

06-03	Nexalin Technology, Inc. Announces FDA Provides Feedback and Reaches Consensus on Nexalin's Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 Halo Clarity Headset Device	CI
05-10	Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 10, 2023 at 10:19 pm

Nexalin Technology, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was USD 0.03056 million compared to USD 0.323322 million a year ago. Net loss was USD 0.748414 million compared to USD 0.393249 million a year ago.

Basic loss per share from continuing operations was USD 0.1 compared to USD 0.08 a year ago.

Latest news about Nexalin Technology, Inc.

Nexalin Technology, Inc. Announces FDA Provides Feedback and Reaches Consensus on Nexalin's Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 Halo Clarity Headset Device	06-03	CI
Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Nexalin Technology Regains Compliance With Nasdaq Listing Requirement	04-25	MT
Nexalin Technology Files $5.6 Million Shelf Registration	04-16	MT
Nexalin Technology Accelerates Manufacturing of Its HALO? Clarity Following Successful Usability, Feasibility, and Electrical Testing	04-09	CI
Nexalin Technology, Inc. Announces the Appointment of William A. Hudson, Jr. to Military & Government Advisory Board	04-02	CI
Top Midday Gainers	03-28	MT
Nexalin Technology, Inc. Announces Positive Results of Clinical Study Validating its Gen-2 TACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego	03-28	CI
Nexalin Technology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Nexalin Technology, Inc. Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman	03-14	CI
Nexalin Technology, Inc. Announces Positive Results from Clinical Study of Its Gen-2 Tacs Device for Treating Adult Patients with Chronic Insomnia	03-06	CI
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device	02-08	CI
Nexalin Technology, Inc. Unveils Gen-3 HALO?? Clarity 15 Milliamp Neurostimulation Device	01-11	CI
Nexalin Technology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Nexalin Technology, Inc. Announces Publication of Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal	16/10/23	CI
Nexalin Technology, Inc. Announces Resignation of Marilyn Elson as Chief Financial Officer	28/09/23	CI
Nexalin Technology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of Its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms	07/08/23	CI
Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization of Nexalin's TACS Devices in the Asia Pacific Region	01/06/23	CI
Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/05/23	CI
Nexalin Technology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	27/03/23	CI
Nexalin Technology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	27/03/23	CI
Certain Warrants of Nexalin Technology, Inc. are subject to a Lock-Up Agreement Ending on 16-MAR-2023.	15/03/23	CI
Certain Common Stock of Nexalin Technology, Inc. are subject to a Lock-Up Agreement Ending on 16-MAR-2023.	15/03/23	CI
Nexalin Technology, Inc. Appoints Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory	24/01/23	CI

Chart Nexalin Technology, Inc.

Duration

Period

More charts

Company Profile

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It also has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Generation 3 or Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.

Sector

Advanced Medical Equipment & Technology

Calendar

06/06/2024 - MicroCap Rodeo Spring into Summer Conference

More about the company

Income Statement Evolution

More financial data

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
NEXALIN TECHNOLOGY, INC.	+75.40%	5.28M
THERMO FISHER SCIENTIFIC	+7.32%	217B
DANAHER CORPORATION	+13.83%	195B
INTUITIVE SURGICAL, INC.	+20.48%	144B
BOSTON SCIENTIFIC CORPORATION	+31.33%	112B
SIEMENS HEALTHINEERS AG	+2.85%	65.83B
EDWARDS LIFESCIENCES CORPORATION	+14.64%	52.67B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+2.72%	49.86B
AGILENT TECHNOLOGIES, INC.	-5.88%	38.18B
GE HEALTHCARE TECHNOLOGIES INC.	+0.25%	35.39B

Other Advanced Medical Equipment & Technology